107474-65-7

Usage

Uses

Used in Pharmaceutical Research:
Methyl pyrrolo<3,2-e>indole-2-carboxylate is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Drug Development:
Methyl pyrrolo<3,2-e>indole-2-carboxylate is used as a potential drug candidate for the treatment of various diseases. Its diverse biological activities, including potential roles in cancer treatment, anti-inflammatory properties, and neurological effects, make it a promising compound for further research and development.
Used in Organic Synthesis:
Methyl pyrrolo<3,2-e>indole-2-carboxylate is used as a building block in the synthesis of complex organic molecules. Its versatile structure allows for the formation of various functional groups and the creation of new compounds with unique properties.

Upstream product

• 1037796-08-9 C₁₂H₁₀N₄O₂ 
• 1074-86-8 4-formyl indole 
• 107474-64-6 methyl 2-azido-3-(1H-indol-4-yl)acrylate 

Downstream Products

• 107474-63-5 methyl 1,2-dihydro-3H-pyrrolo<3,2-e>indole-7-carboxylate 
• 1049812-57-8 C₂HF₃O₂*C₅₃H₅₇ClN₁₀O₉ 
• 1049812-54-5 C₄₃H₄₆ClN₉O₆ 
• 107474-66-8 methyl 3-(tert-butyloxycarbonyl)-1,2-dihydro-3H-pyrrolo<3,2-e>indole-7-carboxylate 
• 105518-47-6 3-carbamoyl-1,2-dihydro-3H-pyrrolo[3,2-e]indole-7-carboxylic acid 

Relevant academic research and scientific papers

CHEMICAL LINKERS AND CLEAVABLE SUBSTRATES AND CONJUGATES THEREOF

The present disclosure provides drug-ligand conjugates and drug-cleavable substrate conjugates that are potent cytotoxins. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them.

CHEMICAL LINKERS WITH SINGLE AMINO ACIDS AND CONJUGATES THEREOF

The present disclosure provides drug-ligand conjugates that are potent cytotoxins and include a linker between the drug and ligand where the linker has a single amino acid. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them.

Studies on the Total Synthesis of CC-1065: Preparation of a Synthetic, Simplified 3-Carbamoyl-1,2-dihydro-3H-pyrroloindole Dimer/Trimer/Tetramer (CDPI Dimer/Trimer/Tetramer) and Development of Methodolodgy for PDE-I Dimer Methyl Ester Formation

Two synthetic preparations of 3-carbamaoyl-1,2-dihydro-3H-pyrroloindole-7-carboxylic acid (2b, CDPI) and the investigation and development of methodology for the preparation of 3-carbamoyl-1,2-dihydro-3H-pyrroloindole dimer 3 (CDPI dimer) constituting the simplified and stable PDE-I dimer skeleton possessing the B-DNA minor groove complementary shape of the natural product CC-1065 are detailed.The extension of this methodology to the preparation of 3-carbamoyl-1,2-dihydro-3H-pyrroloindole trimer 4 and tetramer 5 (CDPI trimer and tetramer) are described and constitute synthetic, potentially selective, high affinity, noncovalent B-DNA minor groove binding agents.